File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Induction of spermatogenesis with gonadotrophins in Chinese men with hypogonadotrophic hypogonadism

TitleInduction of spermatogenesis with gonadotrophins in Chinese men with hypogonadotrophic hypogonadism
Authors
Issue Date1994
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/IJA
Citation
International Journal Of Andrology, 1994, v. 17 n. 5, p. 241-247 How to Cite?
AbstractThe effects of gonadotrophin administration to 17 Chinese patients with hypogonadotrophic hypogonadism (HH) on testicular volume and induction of spermatogenesis were studied. Ten subjects had isolated HH and seven had hypopituitarism. Twelve of the subjects had prepubertal onset of HH and five of them had been treated previously with hCG for induction of puberty. None had a history of cryptorchidism. During hCG treatment for induction of spermatogenesis, all subjects had an increase in serum levels of testosterone into the normal adult male range and their testes increased in size from 3 (1-20) ml to 11.6 (5-20) ml [median(range), p<0.02]. Six subjects required treatment with hCG alone. However, the remaining 11 subjects, after at least 6 months treatment with hCG, required the addition of human menopausal gonadotrophin (hMG) to induce spermatogenesis. Two subjects remained azoospermic. One had a history of mumps orchitis and the other had isolated elevation of blood FSH levels, suggestive of primary testicular failure in addition to HH. Excluding one subject with fertile eunuch syndrome, the mean duration for first appearance of spermatozoa was 13 (4-52) months. Twelve subjects became fertile and pregnancy was achieved in their partners after 20 (4-78) months. The weekly doses for hCG and hMG were 4000 (3000-10000) IU and 225 (225-450) IU, respectively. Patients who responded to hCG alone had a significantly larger pretreatment testicular volume, suggesting that they had only partial gonadotrophin deficiency. Prepubertal onset of hypogonadism was not a determining factor for requirement of hMG treatment. Pretreatment testicular volume correlated positively with the final testicular volume and negatively with the time to achieve spermatogenesis, but not with the final sperm concentration. Previous use of hCG for induction of puberty with resultant testicular growth, favoured a subsequent positive response to hCG. These subjects also required a lower dose of hCG for normalization of serum testosterone levels. In conclusion, gonadotrophins are very effective in stimulating testicular growth and spermatogenesis in subjects with HH, and the positive response to gonadotrophins can be determined by the pretreatment testicular volume.
Persistent Identifierhttp://hdl.handle.net/10722/162025
ISSN
2014 Impact Factor: 3.695
2015 SCImago Journal Rankings: 1.161
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKung, AWCen_US
dc.contributor.authorZhong, YYen_US
dc.contributor.authorLam, KSLen_US
dc.contributor.authorWang, Cen_US
dc.date.accessioned2012-09-05T05:16:44Z-
dc.date.available2012-09-05T05:16:44Z-
dc.date.issued1994en_US
dc.identifier.citationInternational Journal Of Andrology, 1994, v. 17 n. 5, p. 241-247en_US
dc.identifier.issn0105-6263en_US
dc.identifier.urihttp://hdl.handle.net/10722/162025-
dc.description.abstractThe effects of gonadotrophin administration to 17 Chinese patients with hypogonadotrophic hypogonadism (HH) on testicular volume and induction of spermatogenesis were studied. Ten subjects had isolated HH and seven had hypopituitarism. Twelve of the subjects had prepubertal onset of HH and five of them had been treated previously with hCG for induction of puberty. None had a history of cryptorchidism. During hCG treatment for induction of spermatogenesis, all subjects had an increase in serum levels of testosterone into the normal adult male range and their testes increased in size from 3 (1-20) ml to 11.6 (5-20) ml [median(range), p<0.02]. Six subjects required treatment with hCG alone. However, the remaining 11 subjects, after at least 6 months treatment with hCG, required the addition of human menopausal gonadotrophin (hMG) to induce spermatogenesis. Two subjects remained azoospermic. One had a history of mumps orchitis and the other had isolated elevation of blood FSH levels, suggestive of primary testicular failure in addition to HH. Excluding one subject with fertile eunuch syndrome, the mean duration for first appearance of spermatozoa was 13 (4-52) months. Twelve subjects became fertile and pregnancy was achieved in their partners after 20 (4-78) months. The weekly doses for hCG and hMG were 4000 (3000-10000) IU and 225 (225-450) IU, respectively. Patients who responded to hCG alone had a significantly larger pretreatment testicular volume, suggesting that they had only partial gonadotrophin deficiency. Prepubertal onset of hypogonadism was not a determining factor for requirement of hMG treatment. Pretreatment testicular volume correlated positively with the final testicular volume and negatively with the time to achieve spermatogenesis, but not with the final sperm concentration. Previous use of hCG for induction of puberty with resultant testicular growth, favoured a subsequent positive response to hCG. These subjects also required a lower dose of hCG for normalization of serum testosterone levels. In conclusion, gonadotrophins are very effective in stimulating testicular growth and spermatogenesis in subjects with HH, and the positive response to gonadotrophins can be determined by the pretreatment testicular volume.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/IJAen_US
dc.relation.ispartofInternational Journal of Andrologyen_US
dc.subject.meshAdulten_US
dc.subject.meshChinaen_US
dc.subject.meshChorionic Gonadotropin - Administration & Dosage - Pharmacology - Therapeutic Useen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshHumansen_US
dc.subject.meshHypogonadism - Drug Therapy - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMenotropins - Administration & Dosage - Pharmacology - Therapeutic Useen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshSpermatogenesis - Drug Effectsen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleInduction of spermatogenesis with gonadotrophins in Chinese men with hypogonadotrophic hypogonadismen_US
dc.typeArticleen_US
dc.identifier.emailKung, AWC:awckung@hku.hken_US
dc.identifier.emailLam, KSL:ksllam@hku.hken_US
dc.identifier.authorityKung, AWC=rp00368en_US
dc.identifier.authorityLam, KSL=rp00343en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1365-2605.1994.tb01249.x-
dc.identifier.pmid7698849-
dc.identifier.scopuseid_2-s2.0-0027992657en_US
dc.identifier.volume17en_US
dc.identifier.issue5en_US
dc.identifier.spage241en_US
dc.identifier.epage247en_US
dc.identifier.isiWOS:A1994PT08200003-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridKung, AWC=7102322339en_US
dc.identifier.scopusauthoridZhong, YY=7401809110en_US
dc.identifier.scopusauthoridLam, KSL=8082870600en_US
dc.identifier.scopusauthoridWang, C=7501631357en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats